FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2366170493> ?p ?o ?g. }

• W2366170493 endingPage "466" @default.
• W2366170493 startingPage "460" @default.
• W2366170493 abstract "OBJECTIVE A new drug, trans sodium crocetinate (TSC), has been developed to enhance the delivery of oxygen to hypoxic tissues. Cancerous tumors, such as glioblastoma multiforme (GBM), are very hypoxic, and it has been suggested that radiation therapy (RT) is more beneficial if tumors are better oxygenated. A Phase I/II clinical trial was conducted to determine the effect of adding TSC to RT sessions. METHODS An open, single-arm clinical trial incorporating the standard of care (SOC) for GBM was conducted at 18 clinical sites. There were 6 weeks of RT consisting of 2 Gy/day for 5 days/week, beginning after an initial resection or stereotactic biopsy to confirm GBM. Temozolomide (TMZ), 75 mg/m 2 , was given before each RT session. The TSC, 0.25 mg/kg, was intravenously administered around 45 minutes before an RT session 3 days/week, usually on Monday, Wednesday, and Friday. A Phase I run-in period included 2 cohorts. The first cohort contained 3 patients who were given a half dose of the intravenous TSC (that is, 0.25 mg/kg, 3 times per week for only the first 3 weeks of RT). After a Safety Monitoring Committee (SMC) had verified that no dose-limiting toxicity (DLT) had occurred, a second cohort of 6 patients was given the same dosage of TSC but for the full 6 weeks of RT. After the SMC verified that no DLTs had occurred, Phase II began, with the administration of the full 18 doses of TSC. Fifty additional patients were enrolled during Phase II. Following the completion of RT, the patients rested for a month. After that, SOC TMZ chemotherapy (150–200 mg/m 2 ) was administered for 5 days of the 1st week of 6 monthly cycles. No TSC was administered during this chemotherapy phase or later in the trial. Any other follow-up therapies were administered at the discretion of the individual investigators. RESULTS Kaplan-Meier analysis showed that 36% of the full-dose TSC patients were alive at 2 years, compared with historical survival values ranging from 27% to 30% for the SOC. Survival for the biopsy-only subset of patients was 40%, as compared with 42.9% for those patients having a complete resection before treatment. In addition, 2 of the 3 Phase I, Cohort 1 patients survived at 2 years. Contrast MRI data suggested that considerable pseudoprogression had occurred. Both Karnofsky Performance Status (KPS) scores and quality of life (QOL) questionnaires indicated that a good quality of life existed for most patients throughout the trial. No serious adverse events occurring in the trial were attributed to TSC. CONCLUSIONS This trial contained a single arm consisting of 59 patients. The results strongly suggested that adding TSC during RT is beneficial for the treatment of GBM. Trans sodium crocetinate offers a novel, easily implemented way to combat hypoxia in tumor tissue. Clinical trial registration no.: NCT01465347 ( clinicaltrials.gov )" @default.
• W2366170493 created "2016-06-24" @default.
• W2366170493 creator A5025195325 @default.
• W2366170493 creator A5043799073 @default.
• W2366170493 creator A5043879863 @default.
• W2366170493 creator A5064240414 @default.
• W2366170493 date "2017-02-01" @default.
• W2366170493 modified "2023-10-15" @default.
• W2366170493 title "Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme" @default.
• W2366170493 cites W1774006726 @default.
• W2366170493 cites W1971517100 @default.
• W2366170493 cites W1977233926 @default.
• W2366170493 cites W1987480442 @default.
• W2366170493 cites W2004163388 @default.
• W2366170493 cites W2016045856 @default.
• W2366170493 cites W2035546874 @default.
• W2366170493 cites W2088771074 @default.
• W2366170493 cites W2096287682 @default.
• W2366170493 cites W2120800794 @default.
• W2366170493 cites W2124736921 @default.
• W2366170493 cites W2144623714 @default.
• W2366170493 cites W2156330848 @default.
• W2366170493 cites W2181827231 @default.
• W2366170493 doi "https://doi.org/10.3171/2016.3.jns152693" @default.
• W2366170493 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27177177" @default.
• W2366170493 hasPublicationYear "2017" @default.
• W2366170493 type Work @default.
• W2366170493 sameAs 2366170493 @default.
• W2366170493 citedByCount "29" @default.
• W2366170493 countsByYear W23661704932017 @default.
• W2366170493 countsByYear W23661704932018 @default.
• W2366170493 countsByYear W23661704932019 @default.
• W2366170493 countsByYear W23661704932020 @default.
• W2366170493 countsByYear W23661704932021 @default.
• W2366170493 countsByYear W23661704932022 @default.
• W2366170493 countsByYear W23661704932023 @default.
• W2366170493 crossrefType "journal-article" @default.
• W2366170493 hasAuthorship W2366170493A5025195325 @default.
• W2366170493 hasAuthorship W2366170493A5043799073 @default.
• W2366170493 hasAuthorship W2366170493A5043879863 @default.
• W2366170493 hasAuthorship W2366170493A5064240414 @default.
• W2366170493 hasBestOaLocation W23661704931 @default.
• W2366170493 hasConcept C126322002 @default.
• W2366170493 hasConcept C126894567 @default.
• W2366170493 hasConcept C127413603 @default.
• W2366170493 hasConcept C141071460 @default.
• W2366170493 hasConcept C143998085 @default.
• W2366170493 hasConcept C188198153 @default.
• W2366170493 hasConcept C2776194525 @default.
• W2366170493 hasConcept C2777389519 @default.
• W2366170493 hasConcept C29730261 @default.
• W2366170493 hasConcept C2989005 @default.
• W2366170493 hasConcept C31760486 @default.
• W2366170493 hasConcept C502942594 @default.
• W2366170493 hasConcept C509974204 @default.
• W2366170493 hasConcept C535046627 @default.
• W2366170493 hasConcept C71924100 @default.
• W2366170493 hasConcept C72563966 @default.
• W2366170493 hasConcept C78519656 @default.
• W2366170493 hasConceptScore W2366170493C126322002 @default.
• W2366170493 hasConceptScore W2366170493C126894567 @default.
• W2366170493 hasConceptScore W2366170493C127413603 @default.
• W2366170493 hasConceptScore W2366170493C141071460 @default.
• W2366170493 hasConceptScore W2366170493C143998085 @default.
• W2366170493 hasConceptScore W2366170493C188198153 @default.
• W2366170493 hasConceptScore W2366170493C2776194525 @default.
• W2366170493 hasConceptScore W2366170493C2777389519 @default.
• W2366170493 hasConceptScore W2366170493C29730261 @default.
• W2366170493 hasConceptScore W2366170493C2989005 @default.
• W2366170493 hasConceptScore W2366170493C31760486 @default.
• W2366170493 hasConceptScore W2366170493C502942594 @default.
• W2366170493 hasConceptScore W2366170493C509974204 @default.
• W2366170493 hasConceptScore W2366170493C535046627 @default.
• W2366170493 hasConceptScore W2366170493C71924100 @default.
• W2366170493 hasConceptScore W2366170493C72563966 @default.
• W2366170493 hasConceptScore W2366170493C78519656 @default.
• W2366170493 hasIssue "2" @default.
• W2366170493 hasLocation W23661704931 @default.
• W2366170493 hasLocation W23661704932 @default.
• W2366170493 hasOpenAccess W2366170493 @default.
• W2366170493 hasPrimaryLocation W23661704931 @default.
• W2366170493 hasRelatedWork W1968704628 @default.
• W2366170493 hasRelatedWork W2036862336 @default.
• W2366170493 hasRelatedWork W2094385867 @default.
• W2366170493 hasRelatedWork W2589678871 @default.
• W2366170493 hasRelatedWork W2740663609 @default.
• W2366170493 hasRelatedWork W2955195339 @default.
• W2366170493 hasRelatedWork W3200401126 @default.
• W2366170493 hasRelatedWork W4289878317 @default.
• W2366170493 hasRelatedWork W4295758394 @default.
• W2366170493 hasRelatedWork W4306818195 @default.
• W2366170493 hasVolume "126" @default.
• W2366170493 isParatext "false" @default.
• W2366170493 isRetracted "false" @default.
• W2366170493 magId "2366170493" @default.
• W2366170493 workType "article" @default.